Belatacept

Belatacept
Belatacept
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a606016
Licence data US FDA:link
Pregnancy cat. C(US)
Legal status ℞-only (US)
Routes Intravenous
Identifiers
ATC code L04AA28
UNII E3B2GI648A YesY
Chemical data
Formula  ?
 N(what is this?)  (verify)

Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.[2]

References

  1. ^ "Healthvalue.net: CTLA-4 Strategies". http://www.healthvalue.net/ctlaigenglish.html. Retrieved 2008-10-24. 
  2. ^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm. Retrieved 2011-06-16. 
v · d · eImmunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)

purine synthesis inhibitors: Azathioprine • Mycophenolic acid

pyrimidine synthesis inhibitors: Leflunomide • Teriflunomide

antifolate: Methotrexate
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Sirolimus • Deforolimus • Everolimus • Temsirolimus • Zotarolimus • Biolimus A9
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
CTLA-4 (Abatacept, Belatacept) • TNF inhibitor (Etanercept, Pegsunercept) • Aflibercept • Alefacept • Rilonacept

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)


Stub icon This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.